Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity
Jacqueline A. Turner, Malia A. Fredrickson, Marc D’Antonio, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

Immunometabolism of CD8+ T cell differentiation in cancer
Hao Shi, Sidi Chen, Hongbo Chi
Trends in cancer (2024) Vol. 10, Iss. 7, pp. 610-626
Closed Access | Times Cited: 15
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance
Chaojia Chen, Fangcheng Zhao, Jiali Peng, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101686-101686
Open Access | Times Cited: 10
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
Jessica Konen, Haoyi Wu, Don L. Gibbons
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 520-536
Closed Access | Times Cited: 8
Macrophages and T cells in metabolic disorder-associated cancers
Daniel Taranto, Daan J. Kloosterman, Leila Akkari
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 8
Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer
Matthew G.K. Benesch, Xiaoyun Tang, David N. Brindley, et al.
World Journal of Oncology (2024) Vol. 15, Iss. 1, pp. 1-13
Open Access | Times Cited: 7
A novel insight into cancer therapy: Lipid metabolism in tumor-associated macrophages
Yvxiao Ren, Mingjie Wang, Hanghang Yuan, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112319-112319
Open Access | Times Cited: 7
Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy
Prateek Rai, Christopher J. Clark, Vandana Kardam, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 597-597
Open Access
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping, Qixuan Fan, Yi Zhang
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010824-e010824
Open Access
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Kyra Laubach, Tolga Turan, Rebecca Mathew, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 3, pp. 611-41
Open Access | Times Cited: 9
Theoretical Framework and Emerging Challenges of Lipid Metabolism in Cancer
Qiuying Gu, Yuan Wang, Ping Yi, et al.
Seminars in Cancer Biology (2024)
Open Access | Times Cited: 3
Reprogramming T-cell metabolism to enhance adoptive cell therapies
Meghan Kates, Samuel D. Saibil
International Immunology (2024) Vol. 36, Iss. 6, pp. 261-278
Open Access | Times Cited: 2
Regulation of CD8+ T cells by lipid metabolism in cancer progression
Yong Tang, Ziqing Chen, Qianying Zuo, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 11, pp. 1215-1230
Open Access | Times Cited: 2
Disruption of LPA‐LPAR1 pathway results in lung tumor growth inhibition by downregulating B7‐H3 expression in fibroblasts
Fanyi Meng, Zhiyue Yin, Feifei Lu, et al.
Thoracic Cancer (2023)
Open Access | Times Cited: 5
Gene Expression Dysregulation in Whole Blood of Patients with Clostridioides difficile Infection
Maria Tsakiroglou, A.G. Evans, Alejandra Doce Carracedo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12653-12653
Open Access | Times Cited: 1
Regulation of CD8 T‐cell signaling, metabolism, and cytotoxic activity by extracellular lysophosphatidic acid
Raul M. Torres, Jacqueline A. Turner, Marc D’Antonio, et al.
Immunological Reviews (2023) Vol. 317, Iss. 1, pp. 203-222
Closed Access | Times Cited: 4
The Emerging Role of LPA as an Oncometabolite
Theodoros Karalis, George Poulogiannis
Cells (2024) Vol. 13, Iss. 7, pp. 629-629
Open Access | Times Cited: 1
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Kaitlyn Dickinson, Elliott J. Yee, Isaac Vigil, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 1
The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Qiqiang Zhou, Yahong Chen, Ying Liang, et al.
Metabolites (2024) Vol. 14, Iss. 6, pp. 317-317
Open Access
Deleting autotaxin in LysM+ myeloid cells impairs innate tumor immunity in models of metastatic melanoma
Mélanie A. Dacheux, Derek D. Norman, Yoojin Shin, et al.
iScience (2024) Vol. 27, Iss. 10, pp. 110971-110971
Open Access
Secreted phospholipase PLA2G12A-driven lysophospholipid signaling via lipolytic modification of extracellular vesicles facilitates pathogenic Th17 differentiation
Chika Mochizuki, Yoshitaka Taketomi, Atsushi Irie, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Exploring the Effects of Incorporating Different Bioactive Phospholipids into Messenger Ribonucleic Acid Lipid Nanoparticle (mRNA LNP) Formulations
Sunny P. Chen, Shuangyu Wang, Suiyang Liao, et al.
ACS Bio & Med Chem Au (2024) Vol. 5, Iss. 1, pp. 154-165
Open Access
Entering, Linked with the Sphinx: Lysophosphatidic Acids Everywhere, All at Once, in the Oral System and Cancer
D. Roselyn Cerutis, Michael D. Weston, Takanari Miyamoto
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10278-10278
Open Access
Page 1

Scroll to top